Complexities of HCV management in the new era of direct-acting antiviral agents

QJM: An International Journal of Medicine

Volumn 107, Issue 1, 2014, Pages 17-19

  Rosenberg, W M ^a   Tanwar, S ^a   Trembling, P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DIRECT ACTING ANTIVIRAL AGENT; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; DISEASE SEVERITY; EARLY DIAGNOSIS; HEPATITIS C; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIVER CIRRHOSIS; LIVER FIBROSIS; PRIORITY JOURNAL; SUSTAINED VIROLOGICAL RESPONSE; THERAPY RESISTANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL PHENOMENA AND FUNCTIONS; BLOOD; DRUG MONITORING; HEALTH CARE DELIVERY; HEPATITIS C VIRUS; ISOLATION AND PURIFICATION; METHODOLOGY; ORGANIZATION AND MANAGEMENT; REVIEW; SPECIALIZATION; VIROLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; DELIVERY OF HEALTH CARE; DRUG MONITORING; EARLY DIAGNOSIS; HEPACIVIRUS; HEPATITIS C; HUMANS; RNA, VIRAL; SPECIALIZATION; VIRAL LOAD;

EID: 84905766676     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hct181     Document Type: Article

References (10)

1. VICTRELIS™ (boceprevir). Summary of Product Characteristics, 2012. http://www.ema.europa.eu/docs/en_ GB/document_library/EPAR_-_Product_Information/human/002332/WC500109786.pdf (March 2013, date last accessed).
2. INCIVO™ (telaprevir). Summary of Product Characteristics, 2012. http://www.ema.europa.eu/docs/en_GB/document_li brary/EPAR_-_Product_Information/human/002313/WC500115529.pdf (March 2013, date last accessed).
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2011; 55:245-64.
4. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140:370-81.
5. Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Mühlberger N, et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology 2012; 143:974-85.
6. OraQuick HCV Rapid Antibody Test, 2010. http://www.fda. gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm220489.htm (March 2013, date last accessed).
7. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127:1704-13.
8. Harrington PR, Zeng W, Naeger LK. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012; 55:1048-57.
9. Cobb B, Vilchez RA. An update on treatment of hepatitis C virus genotype 1 infection and viral load assessment. Hepatology 2012; 55:979-80.
10. Ferenci P, Reddy KR. Impact of HCV protease-inhibitorbased triple therapy for chronic HCV genotype 1 infection. Antivir Ther 2011; 16:1187-201.